Can You Drink Alcohol on Semaglutide? What Labels and Trials Say
The Ozempic and Wegovy labels list contraindications for MTC/MEN 2 and hypersensitivity, and interactions with insulin and oral drugs. In a 26-week trial, semaglutide cut heavy drinking days by 41.1 vs 26.4 percentage points.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
The FDA prescribing labels for Ozempic and Wegovy list contraindications for a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and for hypersensitivity to semaglutide — worded as serious hypersensitivity in the Ozempic label [1] and known hypersensitivity in the Wegovy label [2]. Their Drug Interactions sections cover two categories: use with an insulin secretagogue (such as a sulfonylurea) or insulin, and use with oral medications, because semaglutide delays gastric emptying and may affect how oral drugs are absorbed [1][2].
Semaglutide’s most common side effects are nausea, vomiting, diarrhea, abdominal pain, and constipation [1]. Two randomized trials — one published in JAMA Psychiatry in 2025 and one in The Lancet on April 30, 2026 — found that semaglutide reduced drinking in adults with alcohol use disorder [5][4][6]. Semaglutide is not FDA-approved for alcohol use disorder; only 3 medications carry that approval [1][2][6].
What do the Ozempic and Wegovy labels list?
The Ozempic label, revised 5/2026, lists two contraindications: a personal or family history of MTC or MEN 2, and a serious hypersensitivity reaction to semaglutide or any of its excipients [1]. The Wegovy label, revised 02/2026, lists a personal or family history of MTC or MEN 2 and known hypersensitivity to semaglutide or any of the excipients in Wegovy tablets or Wegovy injection [2].
The Drug Interactions section of the Ozempic label has two subsections: 7.1, concomitant use with an insulin secretagogue (for example, a sulfonylurea) or with insulin, and 7.2, oral medications [1]. The Wegovy label has the same two subsections, 7.1 and 7.2 [2].
Ozempic is approved for glycemic control in adults with type 2 diabetes, reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [1]. Wegovy is approved for cardiovascular risk reduction, weight reduction, and treatment of noncirrhotic MASH with F2 to F3 fibrosis [2].
Why does alcohol hit different on semaglutide?
The Ozempic label states that the drug delays gastric emptying and may impact the absorption of concomitantly administered oral medications [1]. The Wegovy label says the same and advises increased clinical or laboratory monitoring when it is used with oral medications that have a narrow therapeutic index or require clinical monitoring [2]. Slower stomach emptying is one possible factor in how alcohol feels after drinking, and eating less while on the drug is another.
The drug’s gastrointestinal effects are the other part of the picture. The most common adverse reactions reported in at least 5% of Ozempic patients are nausea, vomiting, diarrhea, abdominal pain, and constipation [1]. In Wegovy’s adult weight reduction trials, severe gastrointestinal adverse reactions were reported in 4.1% of injection-treated patients versus 0.9% of placebo-treated patients [2].
Does Ozempic make you not want to drink?
A phase 2 trial published in JAMA Psychiatry in 2025 offers evidence that semaglutide can reduce drinking, at least in people with alcohol use disorder. The double-blind, randomized study enrolled 48 non-treatment-seeking adults with AUD at a US academic medical center between September 2022 and February 2024, and ran for 9 weeks [5].
Participants received low doses: 0.25 mg per week for 4 weeks, 0.5 mg per week for 4 weeks, and 1.0 mg for 1 week, or placebo [5]. In a laboratory self-administration task, those on semaglutide consumed fewer grams of alcohol and had a lower peak breath alcohol concentration than the placebo group, with medium to large effect sizes [5].
Outside the lab, semaglutide did not change the average number of drinks per calendar day or the number of drinking days, but it did reduce drinks per drinking day and lowered weekly alcohol craving [5]. The authors described this as initial evidence and called for larger trials [5].
What did the 2026 Lancet trial find?
A larger trial published in The Lancet on April 30, 2026, led from Copenhagen University Hospital and conducted at the Mental Health Center Copenhagen, studied 108 treatment-seeking adults aged 18 to 70 with alcohol use disorder and a BMI of 30 or higher, at least 6 heavy drinking days, and an AUDIT score above 15; 88 completed the trial [4][6]. NIH co-authors included NIAAA director George Koob and NIDA director Nora Volkow [4].
Participants were randomized 1:1 to semaglutide 2.4 mg once weekly or placebo for 26 weeks, and all received cognitive behavioral therapy [4][6]. On the four outcomes reported, the semaglutide group had larger reductions than the placebo group:
| Measure (change from baseline) | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Heavy drinking days | -41.1 percentage points | -26.4 percentage points [6] |
| Total alcohol per 30 days | -1550.2 g | -1025.9 g [6] |
| Mean drinks per day | -3.5 units | -2.1 units [6] |
| Body weight | -11.2 kg | -2.2 kg [6] |
Measurements of blood alcohol biomarkers supported the self-reported drinking data [4]. The number needed to treat in this study was 4.3, compared with 7 or higher for approved alcohol use disorder medications [4].
What are the limits of the Lancet trial?
The placebo group also improved substantially, and both arms received cognitive behavioral therapy, so the drug effect is the difference between the two arms, not the full improvement in the semaglutide group [4][6]. No follow-up data were collected after the trial ended, so drinking after week 26 could not be assessed [6]. The participants were mostly White, which may limit how far the results generalize [6].
Gastrointestinal symptoms were the most common adverse effects, including nausea, loss of appetite, vomiting, abdominal pain, reflux, and fatigue [6]. Five participants discontinued due to adverse effects, and one serious abdominal pain event occurred in the semaglutide arm [6]. The authors want longer and larger studies to confirm the findings [4].
Is semaglutide approved for alcohol use disorder?
No. Only 3 medications are FDA-approved to treat alcohol use disorder [6]. The Lancet authors wrote that their findings support an expanded indication for semaglutide, but that indication has not been granted [6]. Ozempic’s approved indications are glycemic control, cardiovascular risk reduction, and kidney outcomes in type 2 diabetes [1], and Wegovy’s are cardiovascular risk reduction, weight reduction, and noncirrhotic MASH with F2 to F3 fibrosis [2].
What about alcohol and low blood sugar on Ozempic?
The labels warn that concomitant use of semaglutide with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia, and that reducing the dose of the insulin secretagogue or insulin may be necessary [1][2]. This is the interaction the labels address directly, and it applies to anyone combining semaglutide with those diabetes drugs.
The Wegovy label adds that in patients with diabetes, blood glucose should be monitored prior to starting and during treatment [2].
Can semaglutide cause dehydration and kidney injury?
The Wegovy label reports postmarketing cases of acute kidney injury, some requiring hemodialysis, in patients treated with semaglutide [2]. The majority of those cases occurred in patients who became dehydrated from nausea, vomiting, or diarrhea — the drug’s own gastrointestinal side effects [2].
Both labels advise monitoring renal function in patients reporting adverse reactions that could lead to volume depletion [1][2]. The Wegovy label specifies that this monitoring matters especially during dosage initiation and escalation [2].
What are the pancreatitis warning signs?
The Wegovy label states that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, and that the drug should be discontinued if pancreatitis is suspected [2]. The symptom to watch for is persistent, severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting [2][7].
On January 29, 2026, the UK’s Medicines and Healthcare products Regulatory Agency strengthened class warnings for GLP-1 and GLP-1/GIP receptor agonists. Between 2007 and October 2025, the MHRA received 1,296 Yellow Card reports of pancreatitis associated with these drugs, of which 19 were fatal and 24 were necrotizing [7]. The MHRA advises using these drugs with caution in people with a history of pancreatitis and not restarting them if pancreatitis is confirmed [7].
The MHRA update applies across the whole class, covering dulaglutide, exenatide, liraglutide, semaglutide, and tirzepatide [7]. The agency also notes that early pancreatitis symptoms can be mistaken for ordinary GLP-1 gastrointestinal side effects, so severe or persistent abdominal pain warrants urgent medical attention rather than being brushed off [7].
Sources
- National Library of Medicine DailyMed. OZEMPIC (semaglutide) injection, solution.
- US Food and Drug Administration. WEGOVY (semaglutide) prescribing information. 2026.
- The Lancet. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.
- National Institutes of Health. Adding weekly GLP-1 to cognitive behavioral therapy further reduces heavy drinking.
- PubMed. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial.
- AJMC. GLP-1s reduce heavy drinking days in patients with obesity, alcohol use disorder. April 30, 2026.
- GOV.UK. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases.
Frequently asked questions
Does Ozempic make you not want to drink?
There is trial evidence in that direction. In a 9-week study of 48 adults with alcohol use disorder, low-dose semaglutide reduced drinks per drinking day and weekly craving, though it did not change average drinks per calendar day or the number of drinking days. A larger 26-week trial found semaglutide cut heavy drinking days by 41.1 percentage points versus 26.4 for placebo.
Why does alcohol hit harder on semaglutide?
The labels state that semaglutide delays gastric emptying and may affect the absorption of things taken by mouth, which is one possible factor in how alcohol feels. Common side effects like nausea, vomiting, and diarrhea can also make drinking more uncomfortable. In Wegovy trials, severe GI reactions occurred in 4.1% of injection patients versus 0.9% on placebo.
Can you drink wine on Wegovy?
Wegovy's contraindications cover a personal or family history of MTC or MEN 2 and known hypersensitivity to semaglutide, and its drug interaction sections cover insulin or insulin secretagogues and oral medications. The labels warn that combining semaglutide with insulin or a sulfonylurea raises hypoglycemia risk, including severe hypoglycemia, and a dose reduction of those drugs may be necessary. Common side effects like nausea, vomiting, and diarrhea can also make drinking uncomfortable.
Is semaglutide approved for alcohol use disorder?
No. Only 3 medications are FDA-approved for alcohol use disorder, and semaglutide is not one of them. Ozempic is approved for type 2 diabetes, cardiovascular risk, and kidney outcomes, and Wegovy for cardiovascular risk, weight reduction, and noncirrhotic MASH. The Lancet authors wrote that their findings support an expanded indication, but it has not been granted.
Does alcohol raise pancreatitis risk on semaglutide?
The pancreatitis warnings for GLP-1s address the drugs themselves. The Wegovy label reports acute pancreatitis, including fatal and necrotizing cases, with GLP-1 receptor agonists, and the UK MHRA logged 1,296 pancreatitis reports across the class between 2007 and October 2025, 19 of them fatal. Severe, persistent abdominal pain warrants urgent medical attention.
What about alcohol and low blood sugar on Ozempic with insulin?
The labels warn that using semaglutide with insulin or an insulin secretagogue, such as a sulfonylurea, may increase the risk of hypoglycemia, including severe hypoglycemia, and that a dose reduction of the insulin or secretagogue may be necessary. The Wegovy label also says patients with diabetes should have blood glucose monitored before and during treatment.
How long were the alcohol trials?
The JAMA Psychiatry trial ran 9 weeks and tested low doses: 0.25 mg per week for 4 weeks, 0.5 mg per week for 4 weeks, and 1.0 mg for 1 week. The Lancet trial ran 26 weeks and used semaglutide 2.4 mg once weekly versus placebo, with everyone also receiving cognitive behavioral therapy. The Lancet team collected no follow-up data after treatment ended.
Do GLP-1s other than semaglutide affect drinking?
The NIH notes that research has increasingly suggested GLP-1s approved for weight loss may benefit people with substance use disorders, and that one earlier clinical trial found a GLP-1 had no effect on heavy drinking in the group as a whole, though a subset with obesity responded strongly. The two randomized trials described here tested semaglutide specifically.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.